Wiesli Matthias Guido, Kaiser Jean-Pierre, Gautier Emanuel, Wick Peter, Maniura-Weber Katharina, Rottmar Markus, Wahl Peter
Laboratory for Biointerfaces, Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland.
Laboratory for Particles-Biology Interactions, Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland.
Bone Joint Res. 2021 Mar;10(3):218-225. doi: 10.1302/2046-3758.103.BJR-2020-0412.
In orthopaedic and trauma surgery, implant-associated infections are increasingly treated with local application of antibiotics, which allows a high local drug concentration to be reached without eliciting systematic adverse effects. While ceftriaxone is a widely used antibiotic agent that has been shown to be effective against musculoskeletal infections, high local concentrations may harm the surrounding tissue. This study investigates the acute and subacute cytotoxicity of increasing ceftriaxone concentrations as well as their influence on the osteogenic differentiation of human bone progenitor cells.
Human preosteoblasts were cultured in presence of different concentrations of ceftriaxone for up to 28 days and potential cytotoxic effects, cell death, metabolic activity, cell proliferation, and osteogenic differentiation were studied.
Ceftriaxone showed a cytotoxic effect on human bone progenitor cells at 24 h and 48 h at concentrations above 15,000 mg/l. With a longer incubation time of ten days, subtoxic effects could be observed at concentrations above 500 mg/l. Gene and protein expression of collagen, as well as mineralization levels of human bone progenitor cells, showed a continuous decrease with increasing ceftriaxone concentrations by days 14 and 28, respectively. Notably, mineralization was negatively affected already at concentrations above 250 mg/l.
This study demonstrates a concentration-dependent influence of ceftriaxone on the viability and mineralization potential of primary human bone progenitor cells. While local application of ceftriaxone is highly established in orthopaedic and trauma surgery, a therapeutic threshold of 250 mg/l or lower should diminish the risk of reduced osseointegration of prosthetic implants. Cite this article: 2021;10(3):218-225.
在骨科和创伤外科中,植入物相关感染越来越多地采用局部应用抗生素进行治疗,这样可以在不引发全身不良反应的情况下达到较高的局部药物浓度。虽然头孢曲松是一种广泛使用的抗生素,已被证明对肌肉骨骼感染有效,但高局部浓度可能会损害周围组织。本研究调查了头孢曲松浓度增加时的急性和亚急性细胞毒性及其对人骨祖细胞成骨分化的影响。
将人原代成骨细胞在不同浓度的头孢曲松存在下培养长达28天,并研究潜在的细胞毒性作用、细胞死亡、代谢活性、细胞增殖和成骨分化。
在浓度高于15000mg/l时,头孢曲松在24小时和48小时对人骨祖细胞显示出细胞毒性作用。在孵育时间延长至10天时,在浓度高于500mg/l时可观察到亚毒性作用。胶原蛋白的基因和蛋白质表达以及人骨祖细胞的矿化水平,分别在第14天和第28天时随着头孢曲松浓度的增加而持续下降。值得注意的是,在浓度高于250mg/l时矿化就受到了负面影响。
本研究证明了头孢曲松对原代人骨祖细胞的活力和矿化潜力具有浓度依赖性影响。虽然头孢曲松的局部应用在骨科和创伤外科中已被广泛应用,但250mg/l或更低的治疗阈值应可降低假体植入物骨整合减少的风险。引用本文:2021;10(3):218-225。